I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology GU Cancer

Genitourinary (GU) Cancer

Roche is leading the investigation of new options for patients suffering from genitourinary cancer, exploring the potential of cancer immunotherapy and treatment tailored to individuals.

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Dec 4 / Roche and Genentech
Disease-free survival and overall survival in patients with high-risk muscle-invasive bladder cancer who have persistent circulating tumor DNA-negative biomarker status post-cystectomy: IMvigor011 study surveillance analysis
This poster reports DFS and OS outcomes in patients with high-risk MIBC who had persistent ctDNA− status post-cystectomy (through 12 months) using data from surveillance arm of the global, double-blind, randomized Phase III IMvigor011 study. 
Oncology Urogenital Cancer SUO-2024

Sign up or login to unlock the full suite of MEDICALLY features
Oct 23 / Roche and Genentech
A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo)
This poster describes the design of a global, open-label, randomised Phase II study evaluating tobemstomig with or without tiragolumab compared with atezolizumab in platinum-ineligible patients with previously untreated, locally advanced or mUC. The study rationale, eligibility criteria, endpoints and enrolment details are reported.
Oncology Urogenital Cancer ESMO-2023

Sign up or login to unlock the full suite of MEDICALLY features
Oct 22 / Roche and Genentech
A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)
This oral presentation reports clinical outcomes with neoadjuvant atezolizumab in patients with invasive non-conventional UC subtypes from the ABACUS-2 clinical study. Data presented include pCR (primary endpoint) and safety.
Oncology Urogenital Cancer ESMO-2023

Sign up or login to unlock the full suite of MEDICALLY features
Feb 17 / Roche and Genentech
Early efficacy results from atezolizumab with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA)
AUREA poster description: This poster reports data from the phase II trial SOGUG-AUREA, evaluating first-line atezolizumab plus split-dose cisplatin in patients with locally advanced or metastatic urothelial carcinoma who are ineligible for full doses of platinum-based chemotherapy. Early efficacy and safety data are presented.
Oncology Urogenital Cancer ASCO-GU-2023

Sign up or login to unlock the full suite of MEDICALLY features
Feb 16 / Roche and Genentech
Circulating Tumor DNA Analysis of IMbassador250: Association of ctDNA Fraction, AR Alterations and Therapy Outcome in mCRPC
IMbassador description: This presentation describes a prospective-retrospective circulating tumor DNA (ctDNA) analysis of the IMbassador250 trial, a phase III international trial which assessed atezolizumab plus enzalutamide vs enzalutamide alone in men with mCRPC. The association between ctDNA fraction and clinical outcomes and the impact of androgen receptor alterations are reported.
Oncology Urogenital Cancer ASCO-GU-2023
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.